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E3 ubiquitin ligases are key enzymes within the ubiquitin proteasome system which catalyze
the ubiquitination of proteins, targeting them for proteasomal degradation. E3 ligases are
gaining importance as targets to small molecules, both for direct inhibition and to be hijacked
to induce the degradation of non-native neo-substrates using bivalent compounds known as
PROTACs (for ‘proteolysis-targeting chimeras’). We describe Homo-PROTACs as an
approach to dimerize an E3 ligase to trigger its suicide-type chemical knockdown inside cells.
We provide proof-of-concept of Homo-PROTACs using diverse molecules composed of two
instances of a ligand for the von Hippel-Lindau (VHL) E3 ligase. The most active compound,
CM11, dimerizes VHL with high avidity in vitro and induces potent, rapid and proteasome-
dependent self-degradation of VHL in different cell lines, in a highly isoform-selective fashion
and without triggering a hypoxic response. This approach offers a novel chemical probe for
selective VHL knockdown, and demonstrates the potential for a new modality of chemical
intervention on E3 ligases.
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E3 ubiquitin ligases are emerging as attractive targets forsmall-molecule modulation and drug discovery1–3. E3sbring a substrate protein and ubiquitin in close proximity to
each other to catalyze the transfer of a ubiquitin molecule to the
substrate4, 5. Substrate ubiquitination can trigger different cellular
outcomes6, of which one of the best characterized is
poly-ubiquitination and subsequent proteasomal degradation7, 8.
The human genome comprises> 600 predicted E3 ligases that
play important roles in normal cellular physiology and disease
states, making them attractive targets for inhibitor discovery9.
However, E3 ligases do not comprise deep and ‘druggable’ active
sites for binding to small molecules2. Blockade of E3 ligase
activity therefore requires targeting of protein–protein interac-
tions (PPIs), and the often extended, ﬂat and solvent-exposed PPI
surfaces make it a challenge for drug design10. Only few potent
inhibitors have been developed to date, mostly compounds that
bind to the E3 substrate recognition site2, 11, for example
MDM212, 13, inhibitor of apoptosis proteins (IAPs)14–16, the von
Hippel-Lindau (VHL) ligase17–19 and KEAP120, 21. Inhibitors of
E3:substrate interaction can exhibit a discrepancy in effective
concentrations between biophysical binding and cellular efﬁ-
cacy19, 22, due to competition from high-afﬁnity endogenous
substrates that markedly increase their cellular concentration as a
consequence of the inhibition. This poses limitations, such as
incomplete blockade of enzyme activity and the need to use high
inhibitor concentrations, which can lead to off-target effects and
cytotoxicity. Moreover, E3 ligases are multi-domain and multi-
subunit enzymes, and targeting an individual binding site leaves
other scaffolding regions untouched and other interactions
functional. As a result, E3 ligase inhibition may be ineffective or
fail to recapitulate genetic knockout or knockdown. New che-
mical modalities to target E3 ligases are therefore demanded.
E3 ligases are not merely targets for inhibition. Compounds of
natural or synthetic origin have been discovered that bind to E3
ligases and promote target recruitment. These interfacial com-
pounds induce de novo formation of ligase-target PPIs, effectively
hijacking E3 activity towards the neo-substrates, for targeted
protein degradation23, 24. One class of hijackers of E3 ligase
activity comprises monovalent compounds. These so-called
‘molecular glues’ include the plant hormone auxin, which binds
to the Cullin RING ligase (CRL) CRL1-TIR1 to target tran-
scriptional repressor proteins of the Aux/IAA family;25 the
immunomodulatory drugs (IMiDs) thalidomide, lenalidomide,
pomalidomide and analog CC-885, that all share binding to
cereblon (CRBN), a subunit of the CRL4-CRBN ligase, and
redirect CRBN activity to different substrates26–31. More recently,
sulfonamide anti-cancer drug indisulam was found to induce
degradation of the splicing factor RBM39 via recruiting CRL4-
DCAF15 activity32, 33. Another class of degrader compounds that
display a similar mechanism of action comprises bivalent mole-
cules known as Proteolysis-Targeting Chimeras (PROTACs).
PROTACs comprise two warheads—one for ligase recruitment
and a second one for target-binding—joined by a linker34. For-
mation of a ternary complex between the PROTAC, the ligase
and the target triggers proximity-induced target ubiquitination
and degradation. Potent and cell-active PROTACs have been
developed for recruiting different ligases, including
CRL2-VHL35–38, CRL4-CRBN39–42, and IAPs43, 44. Targets
successfully degraded by PROTACs include BET proteins Brd2,
Brd3 and Brd435, 37–40, FKBP39, protein kinases36, 41, amongst
others36, 43. An attractive feature of bivalent degrader molecules is
their sub-stoichiometric catalytic activity36, which does not
require full occupancy of the target-binding site as with con-
ventional inhibitors, leading to degrading concentrations that can
be orders of magnitude lower than the inhibitory concentrations
of their constitutive parts alone. Furthermore, induced target
depletion can have a more sustained cellular effect compared to
target inhibition, and can overcome compensatory cellular feed-
back mechanisms, such as increase in target levels45. Crucially,
work from us and others have shown that PROTAC molecules
can exhibit an added layer of selectivity for protein degradation
beyond the intrinsic binding selectivity of the warhead ligand35,
38, 41. Our recent structural work with Brd4-selective PROTACs
targeting CRL2-VHL revealed the importance of speciﬁc ligand-
induced PPIs between the ligase and the target, which contribute
to cooperative formation of stable and highly populated ternary
complexes38.
We hypothesized that it could be possible to trigger an E3
ligase to induce its own degradation, by designing tailored
homo-bivalent PROTACs that recruit two molecules of the same
E3 ligase. The idea was simple, namely that this compound class
could act as chemical inducers of dimerization (CID)46–48,
forming a ternary complex in which the E3 acts as the enzyme
and the neo-substrate at the same time. To provide proof-of-
concept for the approach, we designed, synthesized and tested
homo-bivalent molecules aiming to target CRL2-VHL, the E3
ligase that targets for ubiquitination and degradation the hypoxia
inducible factor alpha subunit (HIF-α) under normoxic condi-
tions49. We show the most active compound, CM11, made of two
instances of a potent hydroxyproline (Hyp) containing VHL
ligand19, avidly forms a 1:2 complex with VHL, and induces
potent and preferential isoform-selective degradation of VHL. We
call these Homo-PROTACs, as a new modality to induce che-
mical knockdown of E3 ligases.
Results
Rational design. Design of VHL Homo-PROTACs began with
careful consideration of the position of derivatization on two
potent VHL ligands recently characterized by our group, VH032
and VH298 (Fig. 1a, b)18, 19. To retain the strong binding
afﬁnity that characterizes the ligand, co-crystal structures were
analyzed to identify solvent-exposed regions from where the
ligands could be derivatized without perturbing their binding
modes (Fig. 1a). This analysis and consideration of previous
VHL-targeting PROTACs pointed to the methyl group of the
left-hand site (LHS) terminal acetyl group of VH032 as a suitable
point of connection for a linker35, 36. A second solvent-exposed
position available for derivatization was the phenyl group on the
right-hand side (RHS), as previously employed with PROTACs
targeting the Halotag50. To investigate the impact of derivatiza-
tion, we designed three classes of Homo-PROTACS: (a) sym-
metric via the LHS acetyl group of each ligand (Fig. 1c); (b)
symmetric via the RHS phenyl group (Fig. 1d); and
(c) asymmetric via the acetyl group in one warhead and the
phenyl in the other (Fig. 1e). In the cases b and c, at the
underivatized terminal LHS we decided to retain either an acetyl
(as in VH032) or a cyano-cyclopropyl moiety (as in VH298), a
modiﬁcation that led to increased binding afﬁnities, cell perme-
ability and cellular activities in the context of the VHL inhibitor
alone19. To evaluate the potential impact of linker length, linkers
comprised of polyethylene glycol chains with either three, four or
ﬁve ethylene glycol units were chosen to connect the two VHL
ligands.
It is known that the trans epimer of Hyp is an absolute
requirement for VHL binding, and that the corresponding cis
epimer abrogates binding to VHL, both within the context of a
native HIF substrate peptide51, and VHL ligands19, 36. We
therefore designed two different PROTACs based on the structure
of the ﬁrst series (Fig. 1c), with the aim to use them as controls: a
cis-cis epimer, expected to be completely inactive, and a cis-trans
epimer compound, expected to retain binding to a single VHL
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molecule in a 1:1 fashion, thus potentially acting as inhibitor but
not as degrader.
Synthesis. For the synthesis of the ﬁrst class of Homo-PROTACs
(Fig. 1c), symmetric PEG linkers 4, 5 and 6 bearing free
carboxylate groups at either ends were obtained by reaction of
tert-butyl bromoacetate with tri-, tetra- and penta-ethylene glycol
in the presence of NaH in dioxane and followed, after puriﬁca-
tion, by treatment with 50% TFA in DCM (Fig. 2).
The ﬁnal compounds CM9, CM10 and CM11 were obtained by
amide coupling of the VHL ligand 7 (prepared as previously
described)35 with linkers 4, 5 and 6, in a 2:1 ratio, respectively, in
the presence of HATU as the coupling agent and DIPEA as the
base (Fig. 2). For the synthesis of the symmetric cis-cis compound
CMP98, compound 835 was coupled with linker 6 to afford the
desired product (Fig. 2). For the preparation of the asymmetric
cis-trans compound CMP99, a synthetic route toward the
synthesis of the monoprotected di-carboxylate linker was estab-
lished. Pentaethylene glycol was the linker of choice because of
ease of puriﬁcation compared to longer PEGs, and at the same
time yielding a control compound of average linker length (PEG-
4 in this case). Pentaethylene glycol was converted in monobenzyl
ether 9 in 71% yield, which was reacted with tert-butyl bro-
moacetic acid under biphasic conditions (DCM / 37% aq. NaOH
and stoichiometric tetrabutyl ammonium bromide). After
deprotection of the benzyl group by catalytic hydrogenation,
formation of the carboxylic acid moiety was achieved by oxida-
tion with TEMPO and bis-acetoxy iodobenzene (BAIB), deliver-
ing compound 11 in 65% yield (Fig. 3). Compound 7 was then
coupled with linker 11 using the condition described above,
affording compound 12. Deprotection of the tert-butyl group
using TFA and subsequently coupling with 8 afforded CMP99 in
66% yield (Fig. 3).
For the synthesis of the second class of symmetric
Homo-PROTACs (Fig. 1d), it was decided to utilize compounds
17 and 18 as VHL warheads. Common precursor 16 was synthesized
following a previously reported procedure50, with minor modiﬁcation
that led to yield and purity improvements (see Supplementary
Notes 1–3). Indeed, we observed that the use of HATU in
combination with HOAT for the coupling steps of both Boc-L-
Hyp and Boc-tert-leucine led to the formation of only the desired
products, avoiding the formation of a bis-acylate secondary
product50, instead prominent when HATU was used alone.
Compound 17 or 18 were obtained by treatment of compound 16
with 1-cyanocyclopropanecarboxylic acid in presence of HATU,
HOAT and DIPEA or acetylimidazole and TEA (see Supplementary
Methods). Synthesis of 17 was also performed using acetic anhydride,
but during this reaction it was observed the formation of a secondary
product di-acetylated, not only at the desired position but also at the
hydroxyl group of the phenyl ring, which could however be
separated. The PEG linkers for this class of compound were designed
to contain a methanesulfonate group at either end, which could be
coupled in a single step with the phenol of the VHL ligand. Linker 19
was prepared by mesylation of pentaethylene glycol and reacted with
either compounds 17 or 18 in a 1:2 ratio in the presence of K2CO3 to
afford CMP106 and CMP108, respectively, in good yield (Scheme 4).
For the synthesis of asymmetric Homo-PROTACs, PEG 10 was
converted in to the mesylated derivative 20 and reacted with 17 or 18
to obtain 21 and 22, respectively in good yield (see Supplementary
Notes 1–3). Final compounds CMP112 and CMP113 were obtained
in good yield upon deprotection of the tert-butyl group and amide
coupling with compound 7 (see Supplementary Notes 1–3).
Biological evaluation. We next tested all our Homo-PROTACs
by monitoring protein levels after 10 h of compound treatment at
1 µM concentration in HeLa cells (Fig. 4a). We observed the
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Fig. 1 Structure-guided design of Homo-PROTACs to induce VHL
dimerization. a Crystal structures of VHL in complex with VH298 (PDB
code 5LLI)19. VHL is shown as a pink surface and the bound ligand as sticks
representation with purple carbons, nitrogen atoms in blue, oxygen in red
and sulphur in dark yellow. b Chemical structure of VHL inhibitors VH032
and VH298. c–e General chemical structures and design of Homo-
PROTACs compounds. Linkage sites at the acetyl and phenyl groups are
indicated in red
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striking effectiveness of CM09, CM10 and CM11 in inducing
VHL depletion in cells (Fig. 4a), and a remarkably selective
degradation for the closely migrating bands corresponding to the
long isoform of VHL52, 53, preferentially over the short isoform.
The VHL gene includes three exons and it encodes two major
isoforms of VHL: a 213 amino-acid long, 30 kDa form (pVHL30)
and a 160 amino-acid long, 19 kDa form (pVHL19). pVHL19
lacks a 53 amino-acid long amino-terminal domain or N-terminal
tail (pVHL-N), which is instead present in pVHL30. Although
both isoforms are expressed in human cells, pVHL19 is the more
prominent form in human tissues54. The most active compounds
are symmetrically linked from the terminal LHS acetyl group of
VH032. Linkage at different positions proved ineffective, sug-
gesting a critical role played by the linking pattern. Control
compounds CMP98 and CMP99 were unable to induce degra-
dation of VHL (Fig. 4a), demonstrating that Homo-PROTAC
activity is dependent on productive bivalent recruitment of VHL
by the trans epimer. The length of the linker also seemed to affect
cellular potency. Indeed, a decrease in effectiveness was observed
at shorter linker lengths, with CM10 and CM11 being the most
active compounds achieving total knockdown of pVHL30, fol-
lowed by CM09 depleting 82% of the target protein. Interestingly,
some degradation of the short isoform pVHL19 was also
observed, albeit low (around 10% depletion). Levels of Cullin2,
the central subunit of the CRL2-VHL complex55, were also
reduced upon treatment with CM10 and CM11 by up to 22%
(Fig. 4a). Treatments with CM10 and CM11 also showed
detectable albeit low increase in protein levels of the hydroxylated
form of HIF-1α (Hdy-HIF-1α, Fig. 4a). As the parent inhibitor
VH032 is completely ineffective at the same concentration of 1
µM (see ref. 19 and vide infra, Fig. 5), this effect cannot be due to
VHL inhibition and is thought to be the result of compound-
induced protein degradation. Levels of HIF-1α were, however,
signiﬁcantly lower than observed when VH032 was used at
concentrations> 100 µM (Fig. 4a, see also ref. 19). VHL knock-
down by siRNA experiments in three different cell lines was
consistent with CM11-induced knockdown, and conﬁrmed that
the bands observed indeed correspond to VHL (Fig. 4b).
It is known that VHL RNAi is insufﬁcient to induce signiﬁcant
HIF stabilization (see also Fig. 4b) and does not cause detectable
upregulation in HIF activity56. On the basis of these considera-
tions, and the relatively low HIF stabilization observed with active
Homo-PROTACs CM09–11 (Fig. 4a), it was presumed that
compound treatment would not induce a HIF-dependent hypoxic
response. To conﬁrm this, we ﬁrst used a luciferase reporter
assay57. Hypoxia response element (HRE) -luciferase reporter
HeLa-HRE and U2OS-HRE cells were treated with different
concentrations of CM11 and at different times, and no increase in
luciferase activity was detected relative to DMSO control
treatment (Supplementary Fig. 1). These results were conﬁrmed
in a quantitative PCR with reverse transcription assay, where no
upregulation of mRNA levels of the known HIF-target genes CA9
was detected (Supplementary Fig. 2). Together the data suggest
that un-degraded pVHL19 is sufﬁcient to maintain low levels of
HIF-1α.
We next turned our attention to further characterize the mode
of action of the protein degradation induced by the active Homo-
PROTACs CM09–11. To interrogate their relative cellular
potency, dose-dependent treatments were performed at two
different time points, 4 and 24 h before harvesting. All
compounds conﬁrmed preferential degradation of pVHL30 in a
concentration-dependent manner, relative to the corresponding
DMSO control (see Fig. 5a for CM11, and Supplementary Fig. 3
for CM09 and CM10). CM11 proved the most potent compound,
inducing complete depletion of pVHL30 after 4 h already at 10
nM (DC99= 10 nM, Fig. 5a). Selective pVHL30 knockdown was
retained after 24 h, with half-degrading concentration (DC50)
between 10 and 100 nM. The effective degrading concentrations
of CM11 are> 3 orders of magnitude lower than the inhibitory
concentrations of the constitutive ligand VH032 alone, which is
only active in cells at ~ 100 µM, underscoring the difference in
cellular efﬁcacy between the two mode of actions. Cellular levels
of Cullin2 decreased by up to 73% upon treatment with CM11
(Fig. 5a). As previously observed, selective pVHL30 knockdown
by Homo-PROTACs resulted in only minor increase in levels of
HIF-1α, relative to hypoxia-inducing controls CoCl2, PHD
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inhibitor IOX2 and VH032 (Fig. 5a). However, when tested at
high micromolar concentrations, Homo-PROTACs acted prefer-
entially as VHL inhibitors over VHL degraders, consistent with
the so-called ‘hook-effect’ whereby formation of binary
1:1 complexes competes with and eventually supersedes the
formation of the productive catalytic 2:1 complex58. Stabilization
of Hdy-HIF-1α upon treatment with all three compounds at
100 µM was indeed comparable with the effect obtained with
VH032 alone (Fig. 5a for CM11, and Supplementary Fig. 3 for
CM09 and CM10). To conﬁrm the cellular activities of
Homo-PROTACs in a different cell line, U2OS cells were treated
for 10 h with CM09, CM10 and CM11 using the same range of
concentrations (1 nM–100 µM). A consistent proﬁle of cellular
activity was observed, conﬁrming that the effects observed are
independent from cell type (Supplementary Fig. 4).
We next interrogated the time-dependent activity of
Homo-PROTACs. Progressive removal of VHL protein over
time was observed, conﬁrming selective depletion of pVHL30
over the short isoform (Fig. 5b for CM11 and Supplementary
Fig. 5 for CM09 and CM10). In particular, CM11 was conﬁrmed
to be the most effective compounds, decreasing pVHL30 level by
more that 70% already after 2 h of treatment, and essentially to
completion after 8 h. The depletion effect was retained up to 12 h;
however, interestingly, pVHL30 levels up to 11% were detected
after 24–36 h treatment, to then decrease again after
48 h. Incomplete degradation of pVHL was observed upon
treatment with CM09, even in the longer time points (Supple-
mentary Fig. 5). The results obtained treating U2OS cells were
consistent with what observed in the previous experiment.
However, in this cell line all three compounds induced complete
degradation of pVHL30 over time (Supplementary Fig. 4). We
hypothesize that this could be due to the different expression
levels of VHL in the two cell lines. CM09 and CM10 achieved
complete degradation of the target protein after 2 h of treatment.
CM11 conﬁrmed to be the most potent compound also in U2OS,
achieving complete degradation of pVHL30 already after 1 h.
Interestingly CM09 lost its cellular efﬁcacy after 36 h. In contrast,
both CM10 and CM11 retained their efﬁcacy even at these longer
time points (Supplementary Fig. 4).
To gain mechanistic insights in the mode of action of
Homo-PROTACs, the dependency on CRL2-VHL and protea-
some activities was examined. The reliance of the
Homo-PROTAC-induced protein degradation on CRL2-VHL
was assessed by inhibiting neddylation of Cullin2 using the NAE1
inhibitor MLN4924, which blocks the activity of CRLs, including
CRL2-VHL59. Proteasome-dependency was interrogated by
treating cells with the proteasome inhibitor MG132. To limit
the known cytotoxicity of MLN4924 and MG132, HeLa cells
where pre-treated with MLN4924 for 3 h followed by MG132 for
30 min before adding CM11 to the media, and cells were
incubated for further 4 h before collecting. Single treatments with
DMSO, MLN4924, MG132 and CM11 and combinations thereof
were performed to disentangle the individual and combined
effects of compound treatments. Degradation of pVHL30 induced
by CM11 was completely abrogated when cells were pre-treated
with MG132, establishing the expected proteasome-dependence
of the chemical intervention (Fig. 6). CM11-induced degradation
was also prevented by pre-treatment with MLN4924, conﬁrming
the dependency on the activity of CRL2VHL (Fig. 6). The same
effect was observed when cells where co-treated with MLN4924
and MG132 before CM11 (Fig. 6). Immunoblots of Cullin2 levels
conﬁrmed the effective blockade of Cul2 neddylation by
MLN4924 (Fig. 6). To assess if CM11 degrading activity was
dependent on VHL binding, a competition experiment was
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performed using the VHL inhibitor VH03219. HeLa cells were
pre-treated with VH032 at 150 µM for 30 min before adding
CM11 into the media. The plates were incubated for further
4 h before harvesting. As expected, VH032 blocked pVHL
degradation (Fig. 6) consistent with the hypothesis that VHL
induces degradation of itself. In contrast, pre-treatment with
IOX4, a PHD2 inhibitor, did not impact CM11 activity (Fig. 6).
To evaluate the speciﬁcity of Homo-PROTAC-induced degra-
dation, and identify potential off-targets, we performed isobaric
tagging mass spectrometry proteomics to quantify degradation at
the proteome level in an unbiased fashion. Amongst the 6,450
detected proteins that passed ﬁltering criteria, no proteins other
than Cul2 were substantially depleted by Homo-PROTACs
CM09, CM10 or CM11 (1 µM for 10 h) compared to DMSO or
VHL inhibitor treatment (Supplementary Data 1). Crucially, no
effect on protein levels of other Cullins (Cul1, Cul3, Cul4A,
Cul4B, Cul5 and Cul7) or CRL-associated subunits was observed
(Supplementary Fig. 6). Together, the data demonstrate that
CM11 mainly induces depletion of pVHL30 and Cul2 but not
other proteins. The proteomics data further evidenced no increase
in protein levels of HIF-1α with Homo-PROTACs (but a small
decrease with CM09) relative to DMSO (Supplementary Fig. 6).
In contrast, treatment with 150 µM VH032 led to increased HIF-
1α levels, as expected (Supplementary Fig. 6).
Biophysical evaluation. Key to the catalytic mode of action of
PROTACs is the formation of a ternary complex36, 38. With
Homo-PROTACs, VHL is presumed to act as both the E3 ligase
and the substrate. Therefore, we next sought to monitor and
biophysically characterize the ternary complex VHL:Homo-
PROTAC:VHL that is thought to underlie cellular activity. To
assess the formation of this ternary complex species in solution,
isothermal titration calorimetry (ITC), size-exclusion chromato-
graphy (SEC) and AlphaLISA proximity assays were performed
(Fig. 7). In ITC titration of CM11 against the VCB complex (VHL
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with Elongin B and Elongin C)60 the stoichiometry of binding (n
value) was found to be 0.6, compared to n= 1 with VH032
(Fig. 7a, Table 1). This result is consistent with CM11 binding to
VHL in a 1:2 molar ratio, in contrast to VH032 that binds to VHL
in a 1:1 ratio18. Notably, the Kd value measured for CM11 was 11
nM (Table 1). Closer examination of the titration curve revealed
that only one point features during the inﬂection of the curve.
Indeed, because the protein concentration used in the experiment
was 20 µM, the c value (deﬁned as [P]tot/Kd) calculated for this
experiment is 2500, which is above the upper limit of c
(~500–1000) that is a prerequisite for precise measurement of
binding afﬁnity. Consequently, this analysis suggests that we may
be underestimating the binding afﬁnity of CM11, i.e., we can
conclude that Kd is ≤11 nM. This corresponds to an avidity (also
known as cooperativity α) of > 18-fold when compared to
VH032. Such large avidity of homo-bivalent molecules has been
observed previously with other systems, for example the BET
inhibitor MT148. The binding interaction between CM11 and
VHL was driven by a large apparent binding enthalpy (ΔΗ
= –12.3 kcal mol−1), whereas the entropic term was slightly
unfavorable (–TΔS= 1.4 kcal mol−1). This observation underlines
how the thermodynamic signature of CM11 is also very different
when compared with that of VH032, in which case the binding
ΔH was around half that observed with CM11, and both the
enthalpic and entropic term contributed favorably to the ΔG of
binding (Table 1). By contrast, the thermodynamic values
obtained for CMP99 binding were entirely consistent with the
ones of VH032 (Table 1). Speciﬁcally, CMP99 bound to VHL in a
1:1 ratio, as expected due to the presence of the cis-Hyp in one of
the two moieties, and it exhibited comparable ΔH and Kd values
to VH032. As anticipated, binding was not detected with CMP98,
the inactive cis-cis epimer. Superposition of integrated heat curves
of CM11, CMP98 and CMP99 is shown in Fig. 7a and visually
highlights the different behaviors of the three compounds.
CM10 showed similar thermodynamic binding parameters rela-
tive to CM11, with n value equal to 0.7 and a low Kd of 32 nM. A
stoichiometry close to 1 was instead found for CM09, suggesting
that at the end of the titration this system was primarily popu-
lated by 1:1 complexes (Supplementary Figs 7 and 8), consistent
with its lower avidity (Table 1)58, 61. To compare and contrast
Homo-PROTACs binding to the long VHL isoform, we expressed
and puriﬁed pVHL30 in complex with Elongin C and Elongin B
(V30CB) and performed ITC titrations (Table 1 and Supple-
mentary Fig. 9). The thermodynamic parameters of binding of
CMP99 to V30CB were comparable to those to V19CB, suggesting
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identical binary target engagement in vitro between the two iso-
forms. CM11 also exhibited large ΔH of binding and n< 1, albeit
interestingly lower avidity for pVHL30 compared to pVHL19
(Table 1 and Supplementary Fig. 9).
SEC experiments showed that V19CB migrates more quickly in
the presence of the active compound CM11 (2:1 protein:ligand
ratio), relative to vehicle control (Fig. 7b). The shifted peak eluted
at a volume corresponding to a species of ~ 90 kDa molecular
weight, based on a calibration run with globular proteins of
known molecular weight (see Methods), suggesting the peak
corresponds to the ternary complex (VCB)2:CM11. Formation of
a 2:1 complex was also observed with V30CB (Supplementary
Fig. 10). Mixing V19CB, V30CB and CM11 resulted in a mixed
population of the three species (V19CB)2:CM11, (V19CB):CM11:
(V30CB) and (V30CB)2:CM11, suggesting that both VHL isoforms
can form ternary complexes with CM11. No shift in VCB was
observed following incubation with inactive CMP98, CMP99 or
ligand VH032. Only in the sample containing CMP99 a small
peak eluted at 13.5 ml (green curve, Fig. 7b). It is possible that
such peak could be due to the formation of a lowly populated
ternary complex. It is interesting that Schoﬁeld and colleagues
observed weak binding of a cis-hydroxyprolyl containing HIF-1α
peptide to VHL51. This weak binding, potentially enhanced by
high avidity in the ternary complex, could be responsible for the
small decrease of VHL levels observed during biological tests in
cells (Fig. 3a). CM10 and CM09 showed formation of a ternary
complex eluting at identical retention volume when compared to
CM11 (Supplementary Fig. 11). No evidence of aggregation was
seen with any of the compounds evaluated, as all observed peaks
eluted well after the void volume.
Lastly, we employed an AlphaLISA proximity assay to compare
ternary complex formation by CM09, CM10 and CM11. The
assay showed the highest intensity signal for CM11, whereas
negligible levels of complex formation were detected for CM09
and CM10 (Fig. 7c). Since SEC detected ternary species with all
three compounds, the minimal intensity detected in the
AlphaLISA likely reﬂects the inability of CM09 and CM10 to
yield a signiﬁcant ternary population at the low concentrations
required for the assay. These results indicate that CM11 is the
most effective Homo-PROTAC at driving ternary complex
formation, consistent with CM11 exhibiting the highest avidity
and full 2:1 stoichiometry in ITC. Together, the biophysical data
supports CM11 as the most cooperative Homo-PROTAC in vitro,
and provides a molecular rationale explaining its potent VHL-
degrading activity inside cells.
Discussion
We describe Homo-PROTACs, a small-molecule approach to
effectively dimerize an E3 ubiquitin ligase to induce its own self-
destruction. Using potent ligands for the E3 ligase VHL, we
developed a series of homo-bivalent molecules that induce
remarkably rapid, profound and selective degradation of the long
isoform of pVHL at nanomolar concentrations. Compound-
induced degradation was exquisitely dependent on the linkage
pattern on the VHL ligand. The most active Homo-PROTAC,
CM11, induces complete depletion of pVHL30 after 4 h already at
10 nM. Potent and selective degradation of pVHL30 was long-
lasting, with a half-degrading concentration (DC50) of <100 nM,
a remarkable increase in cellular activity of >1000-fold compared
to the parent inhibitor VH032. Mechanistically, we show that
CM11 activity is strictly dependent on proteasome activity, Cul2
neddylation, and on VHL binding, and speciﬁcally on the for-
mation of an avid 2:1 complex with VHL. Our data therefore
supports a model in which a highly cooperative ternary complex
(VHL)2:CM11 functions as the key species responsible for the
induced degradation of VHL itself (Fig. 8). Future structural
studies of this ternary species are warranted. Interestingly, CM11
also led to a decrease in cellular levels of Cullin2, which we
hypothesize to be the result of direct ubiquitination and degra-
dation of Cullin2 as part of the CRL2VHL complex. To our
knowledge, it is unprecedented that a PROTAC can induce the
degradation of a protein forming part of the same complex with
the protein targeted directly.
The preferential induced degradation of pVHL30 over the
short VHL isoform was unanticipated and is an intriguing result
of this work. This observation adds to recent evidence from us
and others that chemical degraders designed from inhibitors
recruiting more than a single protein can add a layer of target
degradation selectivity independently of target engagement35, 38,
41. Biophysically, the VHL warhead was found not to distinguish
between the two VHL isoforms at the level of binary target
engagement. It was also found that CM11 does not considerably
distinguish between pVHL19 and pVHL30 within ternary com-
plexes. We therefore view it unlikely that the remarkable selec-
tivity of VHL degradation is due to differences in molecular
recognition. We also consider unlikely that preferential and more
efﬁcient lysine ubiquitination could play a role, because the extra
region present in the long isoform (1–53) does not contain a
single lysine residue. On the other hand, this region is predicted
as intrinsically disordered62, and it has been shown that proteins
containing disordered N-terminal regions are more prone to
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proteasomal degradation63. It is also known that VHL is resistant
to proteasomal degradation when in complex with ElonginB and
ElonginC64, so the form observed to be preferentially depleted
may be free VHL, i.e., not bound to Elongins, or other
proteasome-sensitive forms65. Previous work revealed different
cellular localization patterns of pVHL19 and pVHL30, the former
being primarily nuclear, while the latter predominantly cyto-
plasmic56. Crucially, pVHL30 was found to associate to micro-
tubules, a function that is thought to be independent from its
ligase activity66. We therefore speculate that the selective degra-
dation of pVHL30 observed in cells could be the result of
pVHL19 acting preferentially as part of CRL2-VHL, and pVHL30
as the ‘neo-substrate’. Obtaining a more detailed biochemical and
mechanistic understanding of the cellular mode of action of VHL
Homo-PROTACs is of clear importance for future investigation.
Selective degradation of pVHL30 by CM11 led to minimal
stabilization of HIF-α in cells, and as a result did not trigger
HIF-dependent activity. This is consistent with complete knock-
down of all VHL isoforms being required to achieve effective HIF
stabilization in cells, as observed in vhl–/– cells such as
VHL-deﬁcient renal carcinoma cells49. Our results underscore the
potential beneﬁt of using CM11 to interrogate the biological
function of speciﬁc VHL isoforms, without the masking down-
stream effects of a hypoxic response. Not much is known about
the individual roles of VHL isoforms. Studies have highlighted
how the 53-residue extra region of pVHL30 is not needed for
tumor suppression53, and how both isoforms can have HIF-
dependent tumor suppressor functions in vivo67, 68. Other HIF-
independent roles of pVHL have been proposed69, including a
role for pVHL in collagen assembly70. However, the individual
roles of the different isoforms in these biological functions remain
elusive. Moreover, many HIF-independent roles are thought to be
independent upon Hyp recognition71, and thus cannot be probed
chemically using the current Hyp-based VHL inhibitors19.
Selective and acute knockdown of pVHL30 by CM11 therefore
offers a new opportunity to address these questions.
In summary, we present CM11, a chemical probe for rapid
and selective pVHL30 knockdown. CM11 provides a chemical
tool alternative to conventional knockdown RNAi approaches
and gene editing knockout technologies such as CRISPR-Cas9.
Relevant information to the use of CM11 will be made available
in the newly established ‘Chemical Probes Portal’ (http://www.
chemicalprobes.org/)72. We anticipate CM11 will ﬁnd wide use
amongst chemical and cell biologists alike interested in inves-
tigating and dissecting the pleiotropic biological functions of
pVHL. More generally, we provide proof-of-concept that
bivalent molecules can be designed to induce an E3 ligase to
destroy itself. This strategy opens powerful new avenues to
drugging E3 ligases in ways that are not possible with inhibitors
alone.
Methods
Synthesis of CM09, CM10, CM11 and controls CMP98 and CMP99. General
method A. PEG (1 eq.) was solubilised in dioxane anhydrous and NaH (2 eq.) was
added under stirring. The resulting mixture was stirred at r.t. for 3h. The mixture
was cooled down to 0 °C using ice bath and tert-butylbromo acetate (2 eq.) was
added drop by drop. The resulting mixture was stirred at r.t O/N. The precipitate
was ﬁltered off and the organic phase evaporated to dryness. The resulting oil was
taken up with ethyl acetate, washed with water, dried over MgSO4 and evaporated
to dryness. The resulting oil was puriﬁed by column chromatography using a
gradient of ethyl acetate from 50% to 100% v/v in heptane.
General method B. tert-butyl esters 1, 2, 3 or 12 were dissolved in a solution
of 50% v/v triﬂuroacetic acid in DCM. The resulting solution was stirred for 1 h
or until complete conversion of starting material. The solvent was removed
under high vacuum. The resulting carboxylic acid was used as crude in the next
step without any further puriﬁcation. To a solution of carboxylic acid in 1 ml
DMF were added HATU (1 eq.) and HOBT (1 eq.) and the pH of the reaction
mixture was adjusted to > 9 by addition of DIPEA (3 eq.). The resulting solution
was stirred at room temperature for 5 min and then amine 7 or 8 was added. The
mixture was stirred at room temperature until no presence of the starting
materials was detected by LC-MS. Water was added and the mixture was
extracted with ethyl acetate (×3). The combined organic phases were washed
with brine (×2), dried over MgSO4 and evaporated under reduced pressure to
give the corresponding crude, which was puriﬁed by HPLC using a gradient of
20% to 95% v/v acetonitrile in 0.1% aqueous solution of ammonia to yield the
desired compound.
di‐tert‐butyl 3, 6, 9, 12 – tetraoxatetradecanedioate (1)
Following general method A, from triethylene glycol (1.125 g, 1 ml, 7.49 mmol,
1 eq.) in 10 ml of dioxane, NaH 60% in mineral oil (595.75 mg, 14.9 mmol, 2 eq.)
and tert-Butyl bromoacetate (2.905 g, 2.19 ml, 14.9 mmol, 2 eq.), compound 1 was
obtained as an oil after high vacuum. Yield: 538 mg, 1.42 mmol (19%). ¹H NMR
Table 1 Thermodynamic binding parameters of complex formation of Homo-PROTACs measured by isothermal titration
calorimetry
Protein Compound No. of replicates n Kd (nM) α ΔG (kcal mol−1) ΔH (kcal mol−1) −TΔS (kcal mol−1)
pVHL19 VH032 (ref. 18) 1.030± 0.001 188± 6 – –9.17± 0.02 –5.53± 0.01 –3.65± 0.02
CM11 2 0.6± 0.01 11± 2 18 –10.9± 0.1 –12.3± 0.7 1.4± 0.8
CMP99a 1 0.964± 0.005 146± 2 – –9.33± 0.06 –6.23± 0.05 –3.1± 0.7
CM09 2 0.98± 0.09 41± 15 4 –10.3± 0.2 –6.9± 0.3 –3.5± 0.5
CM10 2 0.73± 0.01 32± 5 6 –10.2± 0.1 –9.4± 0.1 –0.8± 0.2
pVHL30 CM11a 1 0.866± 0.003 25± 3 7.5 –10.4± 0.1 –11.3± 0.1 –0.9± 0.1
CMP99a 1 1.050± 0.004 106± 10 – –9.51± 0.05 –5.19± 0.03 –4.3± 0.1
All titrations were performed at 25 °C. Error values reported are the means± 1 s.e.m., unless otherwise speciﬁed. Raw ITC data are shown for each titration in Fig. 7a and Supplementary Figs 7–9.
aErrors are generated by the Origin program and reﬂect the quality of the ﬁt between the nonlinear least-squares curve and the experimental data.
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Fig. 8 Proposed model for the mechanism of action of Homo-PROTAC
CM11
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(500MHz, CDCl3): δ 3.81 (s, 4H), 3.51–3.46 (m, 12H), 1.26 (s,18H). 13C NMR
(126MHz, CDCl3): δ 169.1, 80.9, 70.1, 70.0, 68.5, 27.5. Analytical data matched
those previously reported73.
di‐tert‐butyl 3,6,9,12,15-pentaoxaheptadecanedioate (2)
Following general method A, from tetrathylene glycol (1.125 g, 1 ml, 5.49 mmol,
1 eq.) in 10 ml of dioxane, NaH 60% in mineral oil (463 mg, 11.5 mmol, 2 eq.) and
tert-Butyl bromoacetate (2.25 g, 1.7 ml, 11.5 mmol, 2 eq.), compound 2 was
obtained as an oil after high vacuum. Yield: 500 mg, 1.18 mmol (10%). ¹H NMR
(500MHz, CDCl3): δ 3.86 (s, 4H), 3.55–3.49 (m, 16H), 1.31 (s, 9H). Analytical data
matched those previously reported73.
di‐tert‐butyl 3,6,9,12,15,18-hexaoxaicosanedioate (3)
Following general method A, from pentaethylene glycol (1.126 g, 1 ml, 4.72
mmol, 1 eq.) in 10 ml of dioxane, NaH 60% in mineral oil (377 mg, 9.45 mmol, 2
eq.) and tert-Butyl bromoacetate (1.872 g, 1.7 ml, 11.5 mmol, 2 eq.), compound 3
was obtained as an oil after high vacuum. Yield: 300 mg, 0,641 mmol (14%). 1H
NMR (400MHz, CDCl3): δ 3.94 (s, 4H), 3.66–3.56 (m, 20H), 1.40 (s, 18H).
Analytical data matched those previously reported73.
N1,N14-bis((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-3,6,9,12-tetraoxatetradecanediamide
(CM09)
Following general method B, from compound 1 (6.80 mg, 0.018 mmol, 1 eq.),
compound 7 (20 mg, 0.045 mmol, 2.5 eq.), HATU (17 mg, 0.045 mmol, 2.5 eq),
HOAT (6.12, 0.045 mmol, 2.5 mmol) and DIPEA (6.98 mg, 0.054 mmol, 3 eq)
compound CM09 was obtained as a white solid. Yield: 8 mg, 0.007 mmol (40%). ¹H
NMR (400MHz, CDCl3): δ 8.61 (s, 2H), 7.48–7.45 (m, 2H), 7.31–7.27 (m, 8H),
7.23 (d, J = 10.2 Hz, 2H), 4.64–4.59 (m, 2H), 4.52–4.46 (m, 4H), 4.41–4.38 (m, 2H),
4.31–4.25 (m, 2H), 4.01–3.94 (m, 4H), 3.82 (d, J= 15.7 Hz, 2H), 3.62–3.52 (m,
12H), 2.45 (s, 6H), 2.42–2.34 (m, 2H), 2.12–2.06 (m, 2H), 1.19 (s, 2H), 0.89 (s,
18H); 13C NMR (101MHz, CDCl3): δ 170.2, 169.9, 169.6, 149.3, 147.5, 137.3,
130.6, 129.9, 128.4, 127.1, 69.9, 69.5, 69.3, 69.1, 57.6, 56.1, 55.9, 42.2, 35.5, 34.6,
25.4, 15.1. HRMS (ESI) m/z: [M +H]+ calculated for: C54H74N8O12S2: 1090.49;
observed: 1091.5093.
N1,N17-bis((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-3,6,9,12,15-
pentaoxaheptadecanediamide (CM10)
Following general method B, from compound 2 (7.60 mg, 0.018 mmol, 1 eq.),
compound 7 (20 mg, 0.045 mmol, 2.5 eq.), HATU (17 mg, 0.045 mmol, 2.5 eq),
HOAT (6.12, 0.045 mmol, 2.5 mmol) and DIPEA (6.98 mg, 0.054 mmol, 3 eq)
compound CM10 was obtained as a white solid. Yield: 6 mg, 0.005 mmol
(30%). ¹H NMR (500MHz, CDCl3): δ p.p.m., 7.58–7.55 (m, 2H), 7.35–7.30
(m, 10H), 4.72–4.67 (m, 2H), 4.57–4.47 (m, 6H), 4.38–4.33 (m, 2H), 4.15–3.91
(m, 8H), 3.68–3.56 (m, 20H), 2.51 (s, 6H), 2.45–2.38 (m, 2H), 2.20–2.14 (m, 2H),
0.95 (s, 18H). 13C NMR (126 MHz, CDCl3): δ 170.3, 169.8, 169.6, 149.6,
146.9, 137.5, 129.5, 128.47, 128.40, 127.1, 70.0, 69.56, 69.52, 69.5, 69.2, 69.1,
57.7, 56.03, 55.98, 42.1, 35.6, 34.6, 25.4, 14.8. HRMS (ESI) m/z: [M + H]+
calculated for: C56H78N8O13S2: 1134.51; observed: 1135.5538.
N1,N20-bis((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-3,6,9,12,15,18-
hexaoxaicosanediamide (CM11)
Following general method B, from compound 3 (8.39 mg, 0.018 mmol, 1 eq.),
compound 7 (20 mg, 0.045 mmol, 2.5 eq.), HATU (17 mg, 0.045 mmol, 2.5 eq),
HOAT (6.12, 0.045 mmol, 2.5 mmol), DIPEA (6.98 mg, 0.054 mmol, 3 eq)
compound CM11 was obtained as a white solid. Yield: 11.74 mg, 0.0099 mmol
(55%). ¹H NMR (400 MHz, CDCl3): δ 8.61 (s, 2H), 7.41–7.38 (m, 2H), 7.29
(t, J = 7.6 Hz, 10H), 4.66–4.61 (m, 2H), 4.49–4.41 (m, 6H), 4.35–4.29
(m, 2H), 3.98–3.91 (m, 6H), 3.62–3.50 (m, 24H), 2.45 (s, 6H), 2.42–2.35
(m, 2H), 2.11–2.06 (m, 2H), 0.88 (s, 18H); 13C NMR (101MHz, CDCl3):
δ 171.2, 170.9, 170.4, 150.3, 148.5, 138.3, 131.6, 130.9, 129.5, 128.1, 71.2,
70.61, 70.59, 70.5, 70.4, 70.3, 58.6, 57.0, 43.2, 36.5, 35.6, 26.4, 16.1. HRMS
(ESI) m/z: [M +H]+ calculated for: C58H82N8O14S2: 1178.54; observed:
1179.6015.
N1,N20-bis((S)-1-((2S,4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-3,6,9,12,15,18-
hexaoxaicosanediamide (CMP98)
Following general method B, from compound 3 (7.12 mg, 0.028 mmol, 1 eq.),
compound 8 (18.06, 0.040 mmol, 2.1 eq.), HATU (15.2 mg, 0.040 mmol, 2 eq.),
HOAT (5.44 mg, 0.040 mmol, 2 eq.), DIPEA (7.45 mg, 0.0010 ml, 3 eq.), compound
CMP98 was obtained as a white solid. Yield: 10.58 mg, 0.0089 mmol (45%). ¹H
NMR (400MHz, CDCl3): δ 9.09 (s, 2H), 8.02 (s, 2H), 7.31 (d, J = 8.5 Hz, 4H), 7.22
(d, J = 8.0 Hz, 4H), 7.16 (d, J = 9.2 Hz, 2H), 4.75–4.64 (m, 4H), 4.51 (d, J= 8.9 Hz,
2H,), 4.41–4.37 (m, 2H), 4.24–4.17 (m, 2H), 3.94 (d, J= 3.2 Hz, 4H), 3.84–3.81
(m, 4H), 3.62–3.54 (m, 20H), 2.49–2.47 (m, 2H), 2.44 (s, 6H), 2.26–2.17 (m, 4H),
0.93 (s, 18H); 13C NMR (101MHz, CDCl3): δ 173.2, 171.5, 169.7, 151.8, 138.8,
132.9, 129.5, 129.2, 128.3, 71.2, 71.1, 70.6, 70.48, 70.45, 70.4, 70.3, 59.9, 58.5, 56.5,
43.2, 35.6, 35.2, 26.4, 15.0. HRMS (ESI) m/z: [M + H]+ calculated for:
C58H82N8O14S2: 1178.54; observed: 1179.6087.
1‐phenyl‐2,5,8,11,14-pentaoxahexadecan-16-ol (9)
Pentaethylene glycol (9.53 g, 50 mmol, 5 eq.) was added dropwise to a
suspension of NaH 60% in mineral oil (800 mg, 20 mmol, 2.5 eq.) in 20 ml of DMF
at 0 °C. The resulting mixture was stirred at r.t for 1 h. The reaction mixture was
cooled to 0oC, benzyl chloride (1 ml, 1.1 g, 8.72 mmol, 1 eq.) was added. The
resulting mixture was stirred O/N at r.t. The reaction was quenched with a
saturated solution of NH4Cl and the aqueous phase was extracted with ethyl acetate
(×3). The combined organic phases were dried over MgSO4 and evaporated to
dryness. The resulting oil was puriﬁed by column chromatography (from 0 to 60%
of ethyl acetate in heptane) to afford the title compound as a oil. Yield: 2.055 g,
6.25 mmol (71%). ¹H NMR (400MHz, CDCl3): δ 7.28–7.19 (m, 5H), 4.50 (s, 2H),
3.66–3.52 (m, 20H), 2.50 (s, 1H). 13C NMR (101MHz, CDCl3): δ 138.2, 128.3,
127.8, 127.6, 73.2, 72.7, 70.61, 70.58, 70.53, 70.51, 70.2, 69.4, 61.7
tert-butyl 1-phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-oate (10)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00954-1
10 NATURE COMMUNICATIONS |8:  830 |DOI: 10.1038/s41467-017-00954-1 |www.nature.com/naturecommunications
To a stirred solution of 9 (2.055 g, 6.25 mmol, 1 eq.) in 12.8 ml of DCM was
added 37% solution of NaOH (12.8 ml), followed by tert-butylbromo acetate
(4.882 g, 25 mmol, 4 eq.) and TBABr (2118 mg, 6.37 mmol, 1.02 eq.). The resulting
solution was stired O/N at r.t. The reaction mixture was extracted with ethyl acetate
(×3). The organic phases were combined and washed with brine (×1), dried over
MgSO4 and concentrate in vacuo. The resulting brow oil was puriﬁed by column
chromatography (from 0 to 30% of ethyl acetate in petroleum) to afford the titled
compound as colorless oil. Yield: 2.216 g, 5 mmol (80%). ¹H NMR (500MHz,
CDCl3): δ 7.28–7.20 (m, 5H), 4.50 (s, 2H), 3.95 (s, 2H), 3.65–3.55 (m, 20H), 1.40
(s, 9H). 13C NMR (126MHz, CDCl3): δ169.7, 128.4, 127.7, 127.6, 81.5, 73.2, 70.7,
70.7, 70.6, 70.6, 69.4, 69.1, 28.1. MS (ESI) m/z: [(M-tBu) + H]+ calculated for:
C23H38O8: 442.26; observed: 387.20.
19,19-dimethyl-17-oxo-3,6,9,12,15,18-hexaoxaicosanoic acid (11)
10 (2.216 g, 5 mmol, 1 eq.) was dissolved in 75 ml of ethanol, Pd/C (10 wt%)
was added and the resulting mixture was place under hydrogen and stirred at r.t.
until complete conversion of the starting material. The reaction mixture was
ﬁltered through celite, the celite pad was washed few times using ethanol. The
ﬁltrate was concentrated in vacuum to give an oil that was used for the next step
without further puriﬁcation. Yield: 1764 g, 5 mmol (quantitative). BAIB (3.546 g,
11.01 mmol, 2.2 eq.) and TEMPO (171.87 mg, 1.10 mmol, 0.22 eq.) were added to a
solution of ACN/H2O 1:1 containing previous obtained oil (1.764 g, 5 mmol, 1 eq.).
The resulting mixture was stirred at r.t until complete conversion of the starting
material. The crude was puriﬁed using ISOLUTE® PE-AX anion exchange column.
The column was equilibrate with methanol, the reaction mixture poured in the
column and let it adsorbed in the pad. The column was washed with methanol (×3)
to elute all the unbound material. Then, the titled product was eluted using a 50%
solution of formic acid in methanol. The organic phase was evaporated to dryness
to afford the title compound as oil. Yield: 1.200 g, 3.27 mmol (65%). ¹H NMR
(400MHz, CDCl3): δ 4.12 (s, 2H), 3.98 (s, 2H), 3.72–3.60 (m, 16H), 1.43 (s, 9H).
13C NMR (101MHz, CDCl3): δ 172.6, 169.7, 81.6, 71.0, 70.59, 70.56, 70.54, 70.46,
70.38, 70.35, 70.30, 68.9, 68.8, 28.1.
tert-butyl (S)-19-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidine-1-carbonyl)-20,20-dimethyl-17-oxo-3,6,9,12,15-pentaoxa-18-
azahenicosanoate (12)
To a solution of PEG linker 11 (78.8 mg, 0.215 mmol, 1 eq.) in 1.5 ml DMF was
added HATU (81.74 mg, 0.215 mmol, 1 eq.), HOAT (29.26 mg, 0.215 mmol, 1 eq.),
DIPEA (80.13 mg, 0.106 ml, 0.645 mmol, 3 eq.) and the solution was stirred at
room temperature for 5 min. Compound 7 (100 mg, 0.215 mmol, 1 eq.) was added
and the pH of the reaction mixture was adjusted to> 9 by addition of DIPEA
(80.13 mg, 0.106 ml, 0.645 mmol, 3 eq.). The mixture was stirred at room
temperature until no presence of the starting materials was detected by LC-MS.
The solvent was evaporated under reduced pressure to give the corresponding
crude, which was puriﬁed by HPLC using a gradient of 20–95% v/v acetonitrile in
0.1% aqueous solution of ammonia to yield the titled compound as white solid.
Yield: 75.6 mg, 0.094 mmol (44%). ¹H NMR (400MHz, CDCl3): δ 9.00 (s, 1H),
7.45 (t, J= 5.9 Hz, 1H), 7.39–7.33 (m, 4H), 7.29 (d, J= 8.9 Hz, 1H), 4.71 (t, J= 8.0
Hz, 1H), 4.59–4.48 (m, 3H), 4.34 (dd, J= 5.2, 14.6 Hz, 1H), 4.08–3.92 (m, 5H),
3.69–3.61 (m, 18H), 2.52 (s, 3H), 2.47–2.41 (m, 1H), 2.19–2.11 (m, 1H), 1.46 (s,
9H), 0.97 (s, 9H). 13C NMR (101MHz, CDCl3): δ 171.3, 171.1, 170.5, 170.0, 151.7,
139.1, 129.4, 128.3, 82.0, 71.1, 70.6, 70.4, 70.4, 70.3, 70.3, 70.2, 70.2, 68.9, 58.7, 57.3,
56.8, 43.1, 36.3, 35.1, 28.1, 26.4, 15.1. MS (ESI) m/z: [M +H]+ calculated for:
C38H58N4O11S2: 778.38; observed: 779.4.
N1-((R)-1-((2R,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N17-((S)-1-((2S,4R)-4-hydroxy-2-
((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-
oxobutan-2-yl)-3,6,9,12,15-pentaoxaheptadecanediamide (CMP99)
Following general method B, from compound 12 (75.6 mg, 0.094 mmol, 1 eq.)
and triﬂuoroacetic acid (1 ml in 1 ml of DCM), the carboxylic acid derivative was
obtained as oil. The crude was used for the next step without further puriﬁcation.
Yield: 70 mg, 0.094 mmol (quantitative). MS (ESI) m/z: [M +H]+ calculated for:
C34H50N4O11S: 722.32; observed: 723.3. Following general method B, from
compound 13 (5.5 mg, 0.006 mmol, 1 eq.), compound 8 (2.77 mg, 0.006 mmol, 1
eq.), HATU (2.28 mg, 0.0.006 mmol, 1 eq.), HOAT (1 mg, 0.0.006 mmol, 1 eq.),
DIPEA (2.23 mg, 0.002 ml, 0.018 mmol, 3 eq.), CMP99 was obtained as a white
solid. Yield: 4.5 mg, 0.004 mmol (66%). ¹H NMR (400MHz, CDCl3): δ 8.74
(s, 1H), 8.73 (s, 1H), 7.37–7.34 (m, 9H), 7.18 (d, J= 8.9 Hz, 1H), 4.76–4.64 (m, 3H),
4.59–4.44 (m, 5H), 4.37–4.26 (m, 2H), 4.05–3.59 (m, 27H), 2.52 (s, 6H), 2.31–2.11
(m, 4H), 0.96 (s, 9H), 0.95 (s, 9H). 13C NMR (101MHz, CDCl3): δ 173.0, 171.3,
170.0, 150.7, 145.4, 138.4, 129.53, 129.49, 128.2, 128.16, 71.2, 71.0, 70.54, 70.48,
70.4, 70.3, 58.4, 57.0, 56.7, 43.4, 35.2, 35.0, 26.4, 26.35, 15.9. HRMS (ESI) m/z: [M
+ H]+ calculated for: C56H78N8O13S2: 1134.51; observed: 1135.5814.
Biological and biophysical assays. Cell culture. Human cell lines HeLa, U2OS
and HEK 293, purchased from ATCC, were propagated in DMEM supplemented
with 10% fetal bovine serum (FBS), L- glutamine, 100 μg ml−1 of penicillin/strep-
tomycin at 37 °C and 5% CO2. Cells were maintained for no more than 30 passages.
All cell lines were routinely tested for mycoplasma contamination using MycoAlert
kit from Lonza. For compound treatment experiments, cells were transferred in
six-well plates with either 3 × 105 or 5 × 105 cells per well in 2 ml of media. At 80%
conﬂuence, cells were treated with compounds at the desired concentration,
reaching ﬁnal DMSO concentration of 0.1% v/v. Cells were incubated at 37 °C and
5% CO2 for the desired time before harvesting.
Small interfering RNA. For siRNA knockdown experiments, 3 × 105 cells were
seeded into each well of a six-well plate in order to achieve 70% of conﬂuence on
the day of transfection. siRNA (SMARTpool: ON-TARGETplus VHL siRNA
L-003936-00-0005) was prepared as a 20 μM solution in RNase-free 1× siRNA
buffer. Negative control siRNA (siRNA from Life Technologies, cat. # 4390843)
was used as negative control. Medium was replaced on the day of transfection.
siRNA solution (5 μL) of both VHL-targeting siRNA and negative control were
added to 250 µl of Opti-mem in 1.5 ml tube. This solution was prepared in
duplicate. Lipofectamine RNAiMax (5 µl) was added to 250 µl of Opti-mem in
another 1.5 ml tube, also prepared in duplicate. The two solutions were combined
and mixed by vortex and incubated at r.t. for 20 min. The whole volume of
transfection mix was added to the six-well plate. Plates were incubated at 37 °C and
5% CO2 for 48 h before harvesting.
ML4924 and MG132 co-treatment. Cells were transferred in six-well plates with
5 × 105 cells per well in 2 ml media in order to achieve 80% conﬂuence the day
after. At t= 0, MLN4924 was added into the desired wells at 3 μM ﬁnal
concentration and 0.1% v/v of DMSO. DMSO (0.1% v/v ﬁnal conc.) was added to
the remaining wells in order to match identical conc. of vehicle in all wells. At t= 3
h, MG 132 was added into the desired wells at 50 μM ﬁnal conc. and 0.1% v/v of
DMSO. DMSO (0.1% v/v ﬁnal conc.) was added to the remaining wells in order to
achieve the same conc. of vehicle in all the wells. At t= 3.5 h, the desired wells were
treated with 1 μM of CM11 in 0.1% v/v DMSO ﬁnal concentration. DMSO (0.1% v/
v ﬁnal conc.) was added to the remaining wells to obtain the same conc. of vehicle
in all the wells. The total ﬁnal concentration of DMSO was therefore 0.3% v/v.
Plates were incubated for 4 h at 37 °C and 5% CO2 before harvesting. For
competition experiments with VH032, cells were treated with VH032 at a ﬁnal
concentration of 150 μM (or IOX4 at 50 μM) for 30 min before treatment with
CM11 at 1 μM ﬁnal concentration for 4 h. Plates were incubated for the desired
time at 37 °C and 5% CO2 before harvesting.
Immunoblotting. Cells were lysed in lysis buffer (20 mM Tris pH 8, 150 mM
NaCl, 1% Triton × 100) and a protease inhibitor cocktail (Roche) per 10 ml buffer.
For protein extracts, the dishes were placed on ice. The media was aspirated and
the tissue layer washed twice with ice-cold phosphate buffer saline (PBS). Lysis
buffer (120 μl) was added and the cells detached from the surface with a cell
scraper. After removal of the insoluble fraction by centrifugation, the protein
concentration of the supernatant was determined by Pierce™ Coomassie (Bradford)
Protein Assay Kit. Protein extracts were fractionated by SDS-PAGE on 4–12%
Tris-Acetate NuPage® Novex® (Life Technologies) polyacrylamide gels and
transferred to a nitrocellulose membrane using wet transfer. The membrane was
then blocked with 5 % w/v Bovine serum albumin (BSA) in Tris-buffered saline
(TBS) with 0.1% w/v Tween-20. For detecting proteins the following primary
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antibodies in the given concentrations were used: anti-β-Actin (Cell Signaling
Technology, 4970S, 13E5) 1:2000, anti-VHL (Cell Signaling Technology, #68547)
1:1000, anti-Hif-1α (BD Biosciences, 610959, clone 54) 1:1,000, anti-hydroxy-HIF-
1α (Hyp564) (Cell Signaling Techonology; #3434) 1:1,000, anti-PHD2 (Bethyl
Laboratories; A300-322A) 1:1,000, anti-PHD3 (Bethyl Laboratories; A300-327A)
1:1000, anti-CRBN (Proteintech; 11435-1-AP) 1:1,000. Following incubation with a
horseradish peroxidase-conjugated secondary antibody (Cell Signaling
Technology), the signal was developed using enhanced chemiluminescence (ECL)
Western Blotting Detection Kit (Amersham) on Amersham Hyperﬁlm ECL ﬁlm
(Amersham). Band quantiﬁcation was performed using ImageJ software and
reported as relative amount as ratio of the each protein band relative to the lane’s
loading control. The values obtained were then normalized to 0.1% DMSO vehicle
control. See Supplementary Fig. 12 for full-scanned images of western-blots shown
in the main text ﬁgures.
Luciferase assay. Assay was performed as described19. Brieﬂy, cells (HeLa and
U2OS) stably expressing an HRE-luciferase reporter were treated for the indicated
times with compounds. Cells were harvested in passive lysis buffer (Promega) and
subjected to three freeze-thaw cycles. The soluble lysate fraction was used for
assays, performed according to the manufacturer’s instructions (Promega) using a
Berthold Lumat LB 9507 Luminometer. Results were normalized for protein
concentration, and reported as mean± s.e.m. from three biological replicates.
Quantitative real-time PCR. Assay was performed as described19. Brieﬂy, RNA
was extracted from HeLa cell lysates using the RNeasy Mini Kit (Qiagen) and
reverse transcribed using the iScript cDNA Synthesis kit (Bio-Rad). Real-time PCR
was performed using PerfeCTa SYBR Green FastMix (Quanta Biosciences) in
C1000 Touch Thermal Cycler (Bio-Rad). mRNA levels were calculated based on
averaged Ct values from two technical replicates, normalized to mRNA levels of β-
actin, and reported as mean± s.e.m. from three biological replicates.
MS proteomics. Sample preparation. HeLa cells were seeded at 5 × 106 on a
10 cm plate 16 h before treatment. Cells were treated with 0.1% DMSO as vehicle
control, VH032 (150 μM) to control for VHL inhibition, and CM09, CM10 or
CM11 (1 μM), reaching a ﬁnal DMSO concentration of 0.1% v/v. Cells were
incubated at 37 °C and 5% CO2 for 10 h before harvesting. Cells were placed on ice
and medium was removed and cells were washed twice with cold PBS. Cells were
lysed in 0.5 ml of 100 mM Tris pH 8.0, 4% (w/v) SDS supplemented with protease
inhibitor cocktail (Roche). The lysate was pulse sonicated brieﬂy and then
centrifuged at 17,000 × g for 15 min at 4 °C. The supernatant fraction of cell extract
was snap-frozen in liquid nitrogen and stored in −80 °C freezer. Further sample
processing, digestion, desalting, labeling and fractionation were performed as
previously described38.
nLC-MS/MS analysis. The TMT 10plex fractions were ﬁrst analyzed as
previously described38. Brieﬂy, the TMT 10plex fractions were analyzed
sequentially on a Q Exactive HF Hybrid Quadrupole-Orbitrap Mass Spectrometer
(Thermo Scientiﬁc) coupled to an UltiMate 3000 RSLCnano UHPLC system
(Thermo Scientiﬁc) and EasySpray column (75 μm× 50 cm, PepMap RSLC C18
column, 2 μm, 100 Å, Thermo Scientiﬁc). The MS2 isolation window was set to
0.4 Da and the resolution set at 120,000. MS2 resolution was set at 60,000. The
AGC targets for MS1 and MS2 were set at 3e6 ions and 1e5 ions, respectively. The
normalized collision energy was set at 32%. The maximum ion injection times for
MS1 and MS2 were set at 50 and 200 ms, respectively. The dynamic exclusion time
was set to 45 s. After the ﬁrst analysis, the TMT labeled fractions were re-analyzed
on the Q-Exactive HF using the same instrument settings and a target list generated
from a theoretical trypsin digest of VHL. In this case only precursor ions that
matched peptide ions from the target list were selected for ms/ms. The dynamic
exclusion time was set to 30 s. After the second analysis, two fractions were further
analyzed using a targeted SIM/ddMS2 method on the Q-Exactive HF. The targeted
list for this run was generated from previous theoretical TMT labeled VHL protein
digest. The methods were as follows, one SIM scan is followed by ﬁve targeted
dd-MS2 scans. The SIM and MS2 isolation windows were set to 6 Da and 0.4 Da,
respectively and the SIM scan and MS2 resolution set at 120,000 and 60,000
respectively. The AGC targets for MS1 and MS2 were set at 1e5 ions and 2e5 ions,
respectively. The normalized collision energy was set at 32%. The maximum ion
injection times for MS1 and MS2 were set at 200 and 300 ms, respectively. The
dynamic exclusion time was set to 3 s.
Peptide and protein identiﬁcation. All the raw MS data ﬁles from the three
analyses were merged and searched against the Uniprot-sprot-Trembl-Human-
Canonical database by Maxquant software 1.5.3.30 for protein identiﬁcation and
TMT reporter ion quantitation. The Maxquant parameters were set as follows:
enzyme used Trypsin/P; maximum number of missed cleavages equal to two;
precursor mass tolerance equal to 10 p.p.m.; fragment mass tolerance equal to 20 p.
p.m.; variable modiﬁcations: Oxidation (M), Acetyl (N-term); ﬁxed modiﬁcations:
Carbamidomethyl (C). The data was ﬁltered by applying a 1% false discovery rate
followed by exclusion of proteins with less than two unique peptides. Quantiﬁed
proteins were ﬁltered if the absolute fold-change difference between the two DMSO
replicates was≥ 1.5.
Protein expression and puriﬁcation. Human proteins VHL (UniProt accession
number: P40337), ElonginC (Q15369), and ElonginB (Q15370) were used for all
protein expression. The short-isoform-containing VCB complex (V19CB) was
expressed, puriﬁed and stored as described previously74. For expression of the
long-isoform-containing VCB complex (V30CB), N-terminally His6-tagged VHL
(1–213), ElonginC (17–112) and ElonginB (1–104) were co-expressed in
Escherichia coli BL21(DE3) at 20 °C for 18 h using 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG). E. coli cells were resuspended in binding buffer
(50 mM HEPES, pH 8.0, 500 mM NaCl, 10 mM imidazole and 5 mM β-
mercaptoethanol), lysed using a pressure cell homogenizer (Stansted Fluid Power),
and lysate clariﬁed by centrifugation. The supernatant was loaded onto a HisTrap
FF afﬁnity column (GE Healthcare) equilibrated with binding buffer, and bound
protein was eluted using an imidazole gradient. The His6 tag was removed using
thrombin protease (Sigma), and the untagged complex was dialyzed into binding
buffer. V30CB was then loaded onto the HisTrap FF column a second time,
allowing impurities to bind as the complex eluted without binding. The
ﬂow-through was dialyzed using a low-salt buffer (20 mM HEPES, pH 8.0, 25 mM
NaCl and 1 mM DTT) and then loaded onto a Resource Q anion exchange column
(GE Healthcare); bound protein was eluted across a linear NaCl gradient. V30CB
was then additionally puriﬁed by size-exclusion chromatography using a Superdex-
75 16/600 column (GE Healthcare) equilibrated with 20 mM HEPES, pH 7.5,
100 mM sodium chloride and 1 mM TCEP. All chromatography puriﬁcation steps
were performed using Äkta FPLC puriﬁcation systems (GE Healthcare).
Isothermal titration calorimetry (ITC). Titrations were performed on an ITC200
micro-calorimeter (GE Healthcare). Homo-PROTACs (CM11, CMP98 or CMP99)
were diluted from a 100 mM DMSO stock solution to 150 µM in a buffer
containing 20 mM Bis-tris propane, 150 mM NaCl, 1 mM tris(2-carboxyethyl)
phosphine (TCEP), pH 7.4. The ﬁnal DMSO concentration was 0.15% v/v. VCB
protein experiments were carried out in a buffer containing 20 mM Bis-tris
propane, 150 mM NaCl, 1 mM TCEP, 0.15% v/v DMSO, pH 7.4. The titrations
consisted of 19 injections of 2 µL compounds solution (150 µM, in the syringe) at a
rate of 0.5 µl s−1 at 120 s time intervals into the VCB protein solution (20 µM, in the
cell). An initial injection of compound solution (0.4 µL) was made and discarded
during data analysis. All experiments were performed at 25 °C, whilst stirring the
syringe at 600 rpm. The data were ﬁtted to a single binding site model to obtain the
stoichiometry n, the dissociation constant Kd and the enthalpy of binding ΔH using
the Microcal LLC ITC200 Origin software provided by the manufacturer.
Size-exclusion chromatography (SEC). SEC experiments were carried out in a
ÄKTA pure system (GE Healthcare) at room temperature. The oligomeric state of
the VCB complex in solution was analyzed by gel ﬁltration in a buffer containing
20 mM Bis-Tris (pH 7), 150 mM NaCl and 1 mM 1,4-dithiothreitol (DTT) using a
Superdex 200 Increase 10/300 GL column (GE Healthcare) calibrated with globular
proteins of known molecular weight (GE Healthcare, 28-4038-41/42). VCB protein
(50 µM) was incubated with CM11 (30 µM), CMP98 (30 µM), CMP99 (30 µM),
VH032 (30 µM) or DMSO (0.5 %) for 20 min at room temperature prior to
injection. Sample volume for each injection was 200 µl, and the ﬂow rate was 0.5
ml min−1. Peak elution was monitored using ultraviolet absorbance at 280 nm.
Biotinylation of VCB. The VCB complex was mixed with EZ-link NHS-PEG4-
biotin (Thermo Scientiﬁc) in a 1:1 molar ratio and incubated at room temperature
for 1 h. The reaction was quenched using 1 M Tris-HCl, pH 7.5, and unreacted
NHS-biotin was removed with a PD-10 MiniTrap desalting column (GE Healthcare)
equilibrated with 20mM HEPES, pH 7.5, 150mM NaCl and 1mM DTT.
AlphaLISA assay. All assays were performed at room temperature in 384-well
plates with a ﬁnal assay volume of 25 µL per well; plates were sealed with
transparent ﬁlm between addition of reagents. All reagents were prepared as
5× stocks diluted in 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine
serum albumin and 0.02% (w/v) 3-[(cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS). Biotinylated VCB (20 nM ﬁnal) and His6-VCB (20 nM
ﬁnal) were incubated with a range of Homo-PROTAC concentrations
(0.5–200 nM; three-in-ﬁve serial dilution) for 1 h. Anti-His acceptor beads
(PerkinElmer, 10 µg ml−1 ﬁnal) were added and plates were incubated for another
hour. Streptavidin-coated donor beads (PerkinElmer, 10 µg ml−1 ﬁnal) were added
and plates were incubated for a ﬁnal 1 h. Plates were read on a PHERAstar FS
(BMG Labtech) using an optic module with an excitation wavelength of 680 nm
and emission wavelength of 615 nm. Intensity values were plotted against
PROTAC concentration on a log10 scale.
Data availability. Data supporting the ﬁndings of this study are available within
the article (and its Supplementary Information ﬁles) and from the corresponding
author upon reasonable request. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identiﬁer PXD007594.
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